Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343241 | 1.00 | TAAR1 (0.47) | TAAR1MEN1KMT2AEPHX1SLC6A2 | |
| SCHEMBL27896536 | 0.81 | TAAR1 (0.41) | TAAR1ALDH1A1TSHRMAOB | |
| SCHEMBL31080676 | 0.81 | TAAR1 (0.44) | TAAR1MEN1KMT2AEPHX1SLC6A2 | |
| SCHEMBL19821211 | 0.80 | TAAR1 (0.41) | TAAR1MEN1KMT2AEPHX1SLC6A2 | |
| SCHEMBL9470007 | 0.80 | ALPI (0.44) | TAAR1MEN1KMT2AHPGDALDH1A1 | |
| SCHEMBL995542 | 0.80 | SLC6A2 (0.44) | TAAR1EPHX1SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL7784340 | 0.79 | TAAR1 (0.43) | TAAR1MEN1KMT2AEPHX1SLC6A2 | |
| SCHEMBL23019073 | 0.79 | HPGD (0.43) | TAAR1MEN1KMT2AEPHX1HPGD | |
| SCHEMBL18376060 | 0.79 | HTR2A (0.51) | HTR2ASIGMAR1CYP2A6CYP1A2MAOB | |
| SCHEMBL12522030 | 0.79 | ADRA2B (0.41) | TAAR1MEN1KMT2AEPHX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954269-B2 | Anti-inflammatory tripeptides | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2021-03-23 | — | — | US | disclosed |
| EP-3769776-A1 | PEPTIDOMIMETIC MACROCYCLES | Aileron Therapeutics, Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| EP-2822572-B1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS INC (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019144805-A1 | SUBSTITUTED PHENYLETHYLAMINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-08-01 | — | — | WO | disclosed |
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2019-05-23 | — | — | US | disclosed |
| US-10227379-B2 | Anti-inflammatory tripeptides | DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) | 2019-03-12 | — | — | US | disclosed |
| WO-2017165299-A2 | COMPANION DIAGNOSTIC TOOL FOR PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-09-28 | — | — | WO | disclosed |
| WO-2017044633-A1 | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 | AILERON THERAPEUTICS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| WO-2017004548-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2017-01-05 | — | — | WO | disclosed |
| WO-2016049355-A1 | PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF | AILERON THERAPEUTICS, INC. (US) | 2016-03-31 | — | — | WO | disclosed |
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-0923569-B1 | BUTYRIC ACID MATRIX METALLOPROTEINASE INHIBITORS | WARNER LAMBERT CO (US) | 2004-11-17 | — | — | EP | disclosed |
| US-6020366-A | Butyric acid matrix metalloproteinase inhibitors | WARNER-LAMBERT COMPANY (US) | 2000-02-01 | — | — | US | disclosed |
| EP-0923569-A1 | BUTYRIC ACID MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1999-06-23 | — | — | EP | disclosed |
| WO-1998006711-A1 | BUTYRIC ACID MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1998-02-19 | — | — | WO | disclosed |
| EP-0148883-B1 | ALLOPURINOL PRODRUGS | A/S GEA Farmaceutisk Fabrik (DK) | 1990-02-14 | — | — | EP | disclosed |
| US-4694006-A | Acyl- or acyloxymethyl-allopurinol prodrugs | A/S GEA (DK) | 1987-09-15 | — | — | US | disclosed |
| EP-0148883-A1 | ALLOPURINOL PRODRUGS. | GEA AS (DK) | 1985-07-24 | — | — | EP | disclosed |
| WO-1985000368-A1 | ALLOPURINOL PRODRUGS | A/S GEA (DK) | 1985-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190153029-A1 | ANTI-INFLAMMATORY TRIPEPTIDES | VIP, TNF, ENPEP | TAAR1 2337/4885MEN1 3418/4885KMT2A 4787/4885 |
| US-10954269-B2 | Anti-inflammatory tripeptides | VIP, TNF, ENPEP | TAAR1 2337/4885MEN1 3418/4885KMT2A 4787/4885 |
| US-10227379-B2 | Anti-inflammatory tripeptides | VIP, TNF, ENPEP | TAAR1 2337/4885MEN1 3418/4885KMT2A 4787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.